Cardiology Today's top 5 articles posted in the last month

Cardiology Today compiled a list of the top 5 stories posted to Healio.com/Cardiology in January.

This month, Cardiology Today readers were most interested in amygdala activity and CV risk, the rise of HF in the United States, late-breaking trials at the upcoming ACC Scientific Sessions, the link between tea consumption and reductions in ischemic heart disease, the possible prevention of U.S. sales of alirocumab due to patent infringement, and much more.

Activity in amygdala predicts CV events

Researchers have linked activity in the amygdala to risk for subsequent CVD, according to findings published in The Lancet. Read More

AHA: Prevalence of HF projected to rise dramatically; CVD still No. 1 killer in US, world

The number of U.S. adults living with HF rose by approximately 800,000 between 2009 and 2014, and is projected to rise 46% by 2030, according to the American Heart Association’s 2017 Heart Disease and Stroke Statistics Update. Read More

ACC late-breaking clinical trials announced

The American College of Cardiology announced the lineup of late-breaking clinical trials scheduled for presentation at its 2017 Scientific Session, including the first CV outcome trials for PCSK9 inhibitors. Read More

Drinking tea daily linked to reduced ischemic heart disease risk in large cohort

In a cohort of more than 487,000 adults in China, the consumption of tea on a daily basis was associated with reduced risk for ischemic heart disease, according to findings published in Heart. Read More

Court grants injunction to prevent US sales of alirocumab due to patent infringement

The U.S. District Court in Delaware has granted an injunction preventing the manufacture, use, sale or offering the sale of the PCSK9 inhibitor alirocumab in the United States due to patent infringement, according to press releases from Amgen and Sanofi/Regeneron. The injunction was delayed pending an appeal by Sanofi/Regeneron. Read More